Geode Capital Management
LENZ

Geode Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Geode Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Buy
564,662
+40,088
+8% +$323K ﹤0.01% 3082
2026
Q1 		$4.8M Buy
524,574
+63,499
+14% +$892K ﹤0.01% 2760
2025
Q4 		$7.38M Buy
461,075
+6,179
+1% +$180K ﹤0.01% 2558
2025
Q3 		$21.2M Buy
454,896
+38,774
+9% +$1.43M ﹤0.01% 1972
2025
Q2 		$12.2M Buy
416,122
+55,730
+15% +$1.52M ﹤0.01% 2231
2025
Q1 		$9.27M Buy
360,392
+26,366
+8% +$649K ﹤0.01% 2336
2024
Q4 		$9.65M Sell
334,026
-3,998
-1% -$122K ﹤0.01% 2403
2024
Q3 		$8.03M Sell
338,024
-22,096
-6% -$490K ﹤0.01% 2498
2024
Q2 		$6.23M Buy
360,120
+271,902
+308% +$4.75M ﹤0.01% 2603
2024
Q1 		$1.97M Buy
88,218
+8,910
+11% +$185K ﹤0.01% 3114
2023
Q4 		$1.45M Buy
79,308
+2,509
+3% +$41.4K ﹤0.01% 3206
2023
Q3 		$1.33M Buy
76,799
+2,775
+4% +$48.3K ﹤0.01% 3210
2023
Q2 		$1.35M Buy
74,024
+38,684
+109% +$773K ﹤0.01% 3240
2023
Q1 		$606K Buy
35,340
+692
+2% +$11.2K ﹤0.01% 3579
2022
Q4 		$805K Buy
34,648
+3,238
+10% +$75.1K ﹤0.01% 3457
2022
Q3 		$696K Buy
31,410
+8,841
+39% +$211K ﹤0.01% 3567
2022
Q2 		$434K Sell
22,569
-37,005
-62% -$825K ﹤0.01% 3842
2022
Q1 		$2.13M Buy
59,574
+21,120
+55% +$1.32M ﹤0.01% 3229
2021
Q4 		$3.35M Buy
38,454
+1,686
+5% +$140K ﹤0.01% 3113
2021
Q3 		$4.22M Buy
+36,768
New +$5.45M ﹤0.01% 3010

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
TI
Trexquant Investment Stamford, Connecticut $17B AUM 39.66% 1-Year Est. Return

Geode Capital Management's LENZ Position: Q2 2026 in Review

Geode Capital Management increased its LENZ Therapeutics (LENZ) stake by 7.6% in Q2 2026, buying an estimated $323K and bringing the position to 564,662 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Geode Capital Management first reported a position in LENZ in Q3 2021 and has held it in 20 quarters since. The position peaked at $21.2M in Q3 2025. 129 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Geode Capital Management held 564,662 shares of LENZ Therapeutics worth $3.21M as of Q2 2026.
  • Geode Capital Management bought 40,088 LENZ Therapeutics shares in Q2 2026, an estimated $323K.
  • LENZ Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3082 holding.
  • Geode Capital Management first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Geode Capital Management's LENZ Therapeutics position peaked at $21.2M in Q3 2025.
  • 129 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.